# Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer

> **NCT05202314** · NA · RECRUITING · sponsor: **Beijing Chao Yang Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Colorectal Cancer
- Neoadjuvant Chemotherapy
- Stent
- Obstruction
- Immunotherapy

## Interventions

- **DRUG:** Immunotherapy (Camrelizumab)

## Key facts

- **NCT ID:** NCT05202314
- **Lead sponsor:** Beijing Chao Yang Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-12
- **Primary completion:** 2023-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05202314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05202314, "Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05202314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*